Compare Revvity Inc (RVTY) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs STMicroelectronics NV — how do they compare? Revvity Inc trades at $154.66 (market cap $16.98B), while STMicroelectronics NV trades at $51.9 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 2.8× Revvity Inc's market cap, and STMicroelectronics NV pays the higher dividend (0.68%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and STMicroelectronics NV for 66 Days on average.
| RVTY | STM | |
|---|---|---|
Market Cap | $16.98B | $48.14B |
Volume | 1,456,900 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $157.36 | $79.91 |
52-Week Low | $82.26 | $21.20 |
Typical Hold Time | 12 Days | 66 Days |
Enterprise Value | $19.30B | $45.66B |
Dividend Yield | 0.18% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
STM trades at $56.18, down 4.33% today, with a bullish technical signal from moving averages. The company shows mixed fundamentals with declining revenue from $17.3B in 2023 to $11.8B in 2025 and negative net income margin of -0.39%, though Q2 2026 earnings beat expectations. Analyst consensus is bullish with a $77.31 price target, and recent news highlights AI data-center revenue potential exceeding $2B by 2027.
Outlook is cautiously optimistic driven by AI and automotive growth catalysts, but risks include profitability challenges and competitive pressures. The stock offers 37% upside to consensus target if execution improves, though investors should monitor margin recovery and debt levels amid volatile semiconductor cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
